MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc Net Income 2011-2026 | PRGO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.43 B | -172 M | -12.7 M | -141 M | -68.9 M | -163 M | 146 M | 131 M | 120 M | -4.01 B | 128 M | 205 M | 442 M | 402 M | 339 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 442 M | -4.01 B | -272 M |
Quarterly Net Income Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.5 M | -8.4 M | -6.4 M | - | -21 M | -108 M | 2 M | - | 14.2 M | 8.4 M | -3 M | - | -49.4 M | -65.1 M | -2.4 M | - | -58.9 M | -57.7 M | 38.1 M | -175 M | -155 M | 60.6 M | 106 M | -19 M | 92.2 M | 9 M | 63.9 M | 81.5 M | -67.5 M | 36.2 M | 80.8 M | 73.1 M | 44.5 M | -69.6 M | 71.6 M | -1.36 B | -1.59 B | -534 M | -529 M | -218 M | 261 M | -22.2 M | 113 M | 151 M | 29.4 M | 70.2 M | 96.3 M | -86 M | 111 M | -86 M | -191 K | 106 M | 106 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 261 M | -1.59 B | -70.6 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.07 | -0.47 % | $ 115 M |  Canada |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | USA |
 |
Harrow Health
HROW
|
-5.14 M | $ 38.95 | -27.32 % | $ 1.43 B | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 2.62 | -0.57 % | $ 1.36 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-49.4 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.74 M | $ 0.55 | -0.97 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 4.5 | -7.02 % | $ 63.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
13.7 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-695 M | $ 3.52 | -5.26 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 2.86 | -4.67 % | $ 377 M | USA |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 8.87 | -1.33 % | $ 454 M | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-332 M | $ 11.92 | 1.24 % | $ 847 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-8.44 M | $ 0.9 | 0.37 % | $ 21 M | USA |
 |
Evolus
EOLS
|
-51.6 M | $ 4.21 | -1.86 % | $ 261 M | USA |
 |
Bausch Health Companies
BHC
|
-592 M | $ 5.77 | -3.11 % | $ 2.11 B | Canada |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.38 | -3.17 % | $ 402 M | Canada |
 |
Sundial Growers
SNDL
|
-230 M | $ 1.53 | 0.33 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 22.06 | 3.67 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-98.8 M | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
67 M | $ 0.73 | -2.19 % | $ 34.9 M | USA |
 |
Solid Biosciences
SLDB
|
-125 M | $ 5.99 | -3.47 % | $ 244 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 2.76 | -2.66 % | $ 3.43 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-10.3 M | $ 2.26 | 1.0 % | $ 23.6 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 7.37 | -2.97 % | $ 4.55 B | Canada |
 |
Veru
VERU
|
-37.8 M | $ 2.54 | -3.05 % | $ 343 M | USA |
 |
Viatris
VTRS
|
54.7 M | $ 15.09 | -3.89 % | $ 18.1 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
-153 K | $ 0.79 | -2.48 % | $ 3.41 M | USA |